What has NICE said?
Enzalutamide (Xtandi) is recommended as a possible treatment for people with metastatic hormone-relapsed prostate cancer who have no or mild symptoms after androgen deprivation treatment has stopped working, and before chemotherapy is needed.
What does this mean for me?
If you have metastatic hormone‑relapsed prostate cancer, and your doctor thinks that enzalutamide is the right treatment, you should be able to have the treatment on the NHS.
Enzalutamide should be available on the NHS within 3 months of the guidance being issued.